Slides
Page 1
1 InnoCare Pharma Interim Results Stock Code: 09969.HK, 688428.SH August 24, 2026
Page 2
2 Disclaimer These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the “Company”) or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The information or opinions contained in these materials has not been independently verified. No representation or warranty, whether expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information and opinions contained in these materials are provided as of the date of the presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. The Company, any of its affiliates, directors, supervisors, senior managers, officers, employees, advisers and their respective representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from or in reliance upon any information contained or presented in or derived from these materials or otherwise arising in connection with these materials. These materials contain statements that reflect the Company’s current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company’s operations and businesses and on factors beyond the Company’s control, and are subject to significant risks and uncertainties, and, accordingly, the actual results may differ materially from these forward-looking statements. You should not place undue reliance on any of such forward-looking information. The Company assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that emerge subsequent to such dates.
Page 3
3 Our Mission & Vison: Science Drives Innovation For The Benefit of Patients AutoimmuneCancer Our Therapeutic Focus To Become a Global Biopharmaceutical Leader that Develops and Delivers Innovative Therapies for Patients Worldwide
Page 4
4 1H 2026: Strong Financial Performance and Accelerating R&D Progress FINANCIAL HIGHLIGHTS ❖ 2026H1: Strong drug sales growth and sustained profitability ➢ Total revenue reached RMB 1,137.1mn, representing a 55.5% yoy growth ➢ Drug sales achieved RMB 918.1mn with 43.2% yoy growth ➢ Net profit reached RMB 239.7 million, reflecting continued strong earnings growth ❖ Cash position: Maintained a solid cash position of ~ RMB 8.4bn by end of 2026H1, providing ample resources to support ongoing R&D and globalization initiatives R&D PIPELINE HIGHLIGHTS ❖ 1 NDA approval: Orelabrutinib for r/r MCL in Australia ❖ 2 NDA submissions: Orelabrutinib for ITP, Zurletrectinib for NTRK+ pediatric patients ❖ 2 Ph3 primary endpoints met: Soficitinib for atopic dermatitis, Fadeucravacitinib for psoriasis ❖ 3 New Ph3 trials initiated: Orelabrutinib for SLE, Mesutoclax + orelabrutinib for r/r MCL, Mesutoclax+AZA vs. Venetoclax+AZA in 1L AML ❖ 2 POC achievements: Soficitinib for Vitiligo, B7H3-ADC ❖ 4 INDs Filed, with 3 Programs Advancing into Clinic: IL-17i, VAV1 molecular glue, CDH17- ADC, PSMA/STEAP1-ADC STRONG FINANCIAL PERFORMANCE AND SIGNIFICANT PROGRESS ACROSS OUR DIVERSIFIED INNOVATION PORTFOLIO
Page 5
5 Advancing Oncology Portfolio with Multiple Approved Products and Key Pipeline Milestones ❖ Orelabrutinib ➢ 1L CLL/SLL NDA approval and NRDL inclusion, constantly expanding growth potential ➢ Overseas progress: approved for r/r MCL in Australia, approved for r/r MCL and r/r MZL in Singapore previously ❖ Tafasitamab ➢ Entering its first full-year of commercial sales in China for r/r DLBCL patients ❖ Mesutoclax (ICP-248) ➢ Combo with Orelabrutinib for 1L CLL/SLL-FDT Ph3 registrational trial - completion expected in 1H2027 ➢ Registrational study for BTKi treated MCL ongoing ➢ Combo with Orelabrutinib for r/r MCL Ph3 registrational trial initiated ➢ Combo with Orelabrutinib for r/r MZL: granted BTD ➢ Mesutoclax + AZA vs venetoclax + AZA: Ph3 registrational study is initiating for elderly/unfit TN-AML ➢ Global Phase 2 trial in MDS ongoing with promising preliminary results FTD: Fixed duration treatment; BTD: Breakthrough Therapy Designation; AZA: Azacitidine, TN: Treatment-Naive Hemato-Oncology Solid Tumor ❖ Zurletrectinib (ICP-723) ➢ Pediatric (2-<12y) NDA accepted with priority review ➢ 2nd-gen pan-TRK inhibitor, Dec-2025 NMPA approval (adult & ≥12y adolescent), commercial sales launched ❖ ICP-B794 (B7-H3 ADC) ➢ Phase I dose escalation ongoing with promising preliminary results ❖ ICP-B208 (CDH17 ADC) ➢ IND approved in May 2026, Phase I dose escalation ongoing ❖ ICP-B381 (PSMA/STEAP1 ADC) ➢ IND submitted and accepted by NMPA in Aug. 2026 ➢ U.S. IND filing expected in Sept. 2026
Page 6
6 ❖ Orelabrutinib ➢ ITP, NDA accepted in 1H2026 ➢ SLE, promising Ph2b data, Ph3 registrational trial ongoing ➢ PPMS & SPMS, Global Ph3 trials advancing with Zenas’s platform ❖ Soficitinib (ICP-332) (TYK2/JAK1) ➢ AD: Ph3 met primary endpoints; NDA planned after safety follow-up ➢ Vitiligo: Ph2 met primary endpoint; advancing to Ph3 ➢ PN: Global Ph2 patient enrollment ongoing ➢ CSU: Phase 2 enrollment completed; data readout by YE2026 ➢ PsO: Phase 2 enrollment completed; data readout by YE2026 ❖ Fadeucravacitinib(ICP-488) (TYK2, allosteric) ➢ PsO: Ph3 registrational trial met its primary endpoints ➢ CLE: Ph2 trial ongoing ➢ SS: Ph2 trial ongoing ➢ More indications under discussion Late-stage Registrational Pipeline Novel early-stage assets ❖ ICP-054 (IL17 small molecule) ➢ Oral IL-17 inhibitor offering a differentiated alternative to injectable biologics ➢ Ex-Greater China & Southeast Asia rights licensed to Zenas, with Phase I completion expected by YE2026 ❖ ICP-538 (VAV1 molecular glue) ➢ Potential first-in-class VAV1 molecular glue degrader targeting a novel immune regulatory pathway ➢ Phase I study is expected to complete by YE2026, with Phase I data expected to provide initial safety, PK/PD and target engagement insights ❖ Multiple programs advancing toward clinical development Advancing a Broad Autoimmune Portfolio Toward Commercialization, with First-in-Class Potential in Next-Wave Assets
Page 7
7 Innovative Pipeline: Accelerating Portfolio Towards Value Realization Pre-IND Phase 1/2 Phase 3 Registration Approved Hemato-oncology Autoimmune Disease Solid Tumors Mesutoclax (ICP-248) BCL2 r/r NHL(CHN, US) AML(Global) MDS (CHN, Global) Soficitinib (ICP-332) TYK2/JAK1 Prurigo nodularis (Global) Psoriasis (CHN) Fadeucravacitinib(ICP-488) TYK2 CLE (CHN) Sjö gren's syndrome (CHN) ICP-538 VAV1 Autoimmune diseases (CHN) ICP-054 IL-17AF* Autoimmune diseases (CHN) ICP-B794 (ADC) B7H3 Solid Tumors (CHN) ICP-B208(ADC) CDH17 Solid Tumors (CHN) ICP-B381(BsAb-ADC) Prostate Cancer Orelabrutinib BTK TN MCL (Global) MZL confirmatory (CHN) SLE (CHN) PPMS (Global)* SPMS (Global)* Tafasitamab CD19 DLBCL (CHN) Mesutoclax BCL2 TN CLL/SLL (CHN) +Orela BTKi failure r/r MCL Phase 2 registrational r/r MCL +Orela r/r MZL +Orela 1L AML(CHN) +AZA vs.Ven.+AZA Soficitinib (ICP-332) TYK2/JAK1 Atopic Dermatitis (CHN) Vitiligo (CHN) Phase 2/3 CSU (CHN) Phase 2/3 ICP-488 TYK2 Psoriasis (CHN) Orelabrutinib BTK ITP (CHN) Zurletrectinib NTRK NTRK fusion-positive cancers in pediatric patients (CHN) Orelabrutinib BTK TN CLL/SLL (CHN) r/r CLL/SLL (CHN) r/r MCL (CHN) r/r MCL (SG) r/r MCL (AU) r/r MZL (CHN) r/r MZL (SG) Tafasitamab CD19 r/r DLBCL (CHN Mainland) r/r DLBCL (GBA) r/r DLBCL (HK) r/r DLBCL (Macao) r/r DLBCL (TW) Zurletrectinib NTRK NTRK fusion-positive cancers (CHN) Degrader Oral Autoimmune diseases Biologics Solid tumor IBD Others Oral Autoimmune diseases * Partnered with Zenas BioPharma (Nasdaq: ZBIO) BsAb-ADC BsAb PSMA/STEAP1
Page 8
8 Total Revenue in first half 2026 achieved 55.5% yoy growth, of which Drug Sales growing 43.2% yoy with a Diversified Portfolio Note: : The above financials are based on HKFRS (Hongkong Financial Reporting Standards) Drug Sales include products revenue of Orelabrutinib, tafasitamab, and Zurletrectinib • Total Revenue achieved 55.5% yoy growth - Drug sales continued robust growth - BD milestone payments recognized in 2026 H1 • Drug sales achieved 43.2% yoy growth, more commercialized products with new indications ensuring continued high growth - Expanded market for Orelabrutinib after 1L CLL/SLL approval and further penetration in high-potential MZL market - Contributions from a diversified portfolio following the launches of Tafasitamab and Zurletrectinib - Enhanced commercial execution to gain more market share In RMB millions Total Revenue Drug Sales In RMB millions 90 641 2025 H1 219 918 2026 H1 731 1,137 +55.5% yoy growth BD and service Drug sales 2025 H1 2026 H1 641 918 +43.2% yoy growth
Page 9
9 Sustainable Profitability Backed by Strong Cash Reserves R&D Expense R&D expenses increased for strategic investment for innovative technology platform, increased resources to clinical trials for our prioritized programs Profit/(Loss) for the Period Cash and related balance* Robust cash and related account balance of RMB 8.4B (~US$1.24B) provides flexibility to expedite the clinical development and to invest in a competitive pipeline Note: The above financials are based on HKFRS (Hongkong Financial Reporting Standards) Cash and related balance includes cash and bank balance, financial assets balance and interest receivables balance In RMB millions 2025 H1 2026 H1 -36 240 450 497 2025 H1 2026 H1 +10.5% 7,814 8,431 2025 Dec 31 2026 Jun 30 In RMB millions In RMB millions InnoCare continued to be profitable in the first half 2026, reporting a profit of RMB 240M (Diluted EPS RMB 0.14). This achievement was primarily attributable to a strong drug revenue growth, BD milestone revenue recognized, alongside the improved cost efficiency.
Page 10
10 Orelabrutinib + Tafasitamab + Zurletrectinib: Diversified Product Portfolio Driving Continued Commercial Growth （RMB Mn） 49% 215 566 671 1001 1443 2021 2022 2023 2024 2025 2026E +35% 1Indications included in NRDL: adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (1L CLL/SLL), adult patients with mantle cell lymphoma who have received at least one prior therapy (r/r MCL), and adult patients with marginal zone lymphoma who have received at least one prior therapy (r/r MZL) +43% Orelabrutinib Tafasitamab Zurletrectinib Orelabrutinib Tafasitamab Zurletrectinib ✓ Durable deep responses, strong CNS penetration, and favorable overall safety profile ✓ China’s first domestically developed next- generation TRK inhibitor with tumor- agnostic potential ✓ Demonstrated ability to overcome resistance to first-generation TRK inhibitors ✓ Excellent efficacy and safety profile ✓ Once-daily dosing ✓ Largest patient population coverage in NHL (CLL/SLL, MCL, MZL) among BTKi in CN ✓ First and only BTKi for the treatment of r/r MZL ✓ Recommended in the 2026 CSCO Lymphoma Guidelines: CLL/SLL (1L & r/r) – Grade I; MCL (1L) – Grade II, (r/r) – Grade I; MZL (r/r) – Grade I, 1L (in combination with rituximab) – Grade II; PCNSL (1L, in combination with HD-MTX and rituximab) – Grade II. ✓ High response rates and durable remissions ✓ The first CD19-targeted antibody approved in Greater China for r/r DLBCL ✓ Recommended in the 2026 CSCO Lymphoma Guidelines: r/r DLBCL – Class I; r/r FL (in combination with rituximab and lenalidomide) – Class I Strong commercial execution driving sustained growth
Page 11
11 A Leading Hemato- oncology Franchise
Page 12
12 Hemato-oncology: Leading Commercializing Proven Portfolio and Advancing Next-Generation Therapies for Broader Markets r/r CLL/SLL r/r MCL r/r MZL 1L CLL/SLL 1L MCL MZL Confirmatory Trial r/r DLBCL DLBCL Confirmatory Trial 1L CLL/SLL r/r MCL (BTKi treated) r/r MCL r/r MZL 1L AML 1L MDS Orelabrutinib Mesutoclax (ICP-248) BTK Tafasitamab CD19 BCL2 +Orela, Ph3, patient enrollment completed Ph2 registrational trial Global Ph3 ongoing Ph3 ongoing Assets Target Indication Clinical Trial Registration Market CHN,SG,AU CHN CHN, SG CHN, HK, MC, TW Ph3 ongoing CHN +Orela, Ph3 registrational trial Market Registration trial +Orela, Ph3 registrational trial +AZA vs Ven+AZA, Ph3 registrational trial Dose escalating ongoing in CHN & global
Page 13
13 Enhanced ADCP (Fc portion)CD19 Direct cytotoxicity (CD19 binding site) B cell Enhanced ADCC (Fc portion) Malignant Natural killer cell Macrophage Lenalidomide Tafasitamab Source: Cheson BD, et al. Blood Cancer J. 2021;11:68–78. Frost & Sullivan Analysis as of the end of 2022; Insight; Pharma Intelligence Comparison of Selected Novel Therapy in r/r DLBCL Company Target Therapy Phase ORR (%) CR (%) mDOR (m) mPFS (m) mOS (m) Incyte/ InnoCare CD19 Tafasitamab + Lenalidomide Approved ex-China 57.5 40 43.9 11.6 33.5 ADC Therapeutics CD19 ADC Loncastuximab tesirine Approved ex-China 48.3 24.1 10.25 4.93 9.92 Roche CD79b ADC Polatuzumab vedotin + BR Approved 42 23 12.6 9.5 12.4 Roche CD20/ CD3 Glofitamab BLA 52 39 10.4 3.8 11.5 Amgen/ Beigene CD19/ CD3 Blinatumomab II 43 19 11.6 3.7 5.0 Regeneron/ Zai Lab CD20/ CD3 Mosunetuzum ab II 33 21 N/A N/A N/A AbbVie BCL-2 Venetoclax+R +Pola II 65 31 5.8 4.4 11 Non-head-to-head comparison Tafasitamab: Best Medicine Potential to Deliver Unique Clinical Value for DLBCL Patients
Page 14
14 Mesutoclax (ICP-248): A Novel BCL-2 Inhibitor with Great Clinical Advantages Soft-spot blocked Venetoclax Pharmacological Properties Advantages of Mesutoclax M27, a major metabolite of Venetoclax, shows ~80% AUC of the parent drug within 24 h Significant inhibition of CYP2C8 and CYP2C9 by Venetoclax and M27 with IC50 ≤ 0.82 µ M Significant inhibition of P-gp and BCRP by Venetoclax and M27 with IC50 ≤ 1.48 µ M Reduced hematological toxicity Significantly higher exposure Eliminated major metabolite Reduced DDI risks CYP: Cytochrome P450 proteins; BCRP: breast cancer resistance protein; DDI: drug-drug interaction; PK: Pharmacokinetics M27 has no pharmacological activity but has hematological toxicity* * Venetoclax FDA non-clinical toxicology review Excellent efficacy & safety profile
Page 15
15 Favorable PK Profiles Compared with Venetoclax in Clinical Studies Source: Venclexta (venetoclax) FDA Clinpharm Review Comparison of PK Profiles ICP-248 (100/125 mg, QD) vs Venetoclax (400 mg, QD) 0 4 8 12 16 20 24 0 2 4 6 8 10 Time (hr) Plasma concentration (μM) ICP-248, 100 mg, n=12 Venetoclax, 400 mg, n=9 ICP-248, 125 mg, n=3 ~2X ✓PK exposure of ICP-248 at 125 mg QD is 3 times of Venetoclax at 400 mg QD Data cut off: 2025.03.26 ~3X
Page 16
16 Mesutoclax (ICP-248): Strengthening Our BTK + BCL-2 Franchise to Drive Leadership in NHL Ibru + Ven1 Acala + Ven2 Sample Size 42 106 291 ORR 100% 86.8% 92.8% CRR 52.4%* 36.7% NA uMRD 65%** W36 45.3% EOT+3 34.4% EOT TLS 0 0 0.3% Orela+Mesutoclax Venetoclax3,4 Pirtobrutinib5 BTKi+, N=25 BTKi+, N=17 cBTKi* Pretreated MCL N=90 ORR 84% 53% 57.8% CRR 36% 18% 20.0% Mesutoclax * cBTKi: covalent Bruton tyrosine kinase inhibitor 1. NEJM Evid 2022;1(7) 2. ASH 2024 3.doi:10.3324/haematol.2018.198812 4.doi.org/10.1182/bloodadvances.202200 8916 5.doi:10.1200/JCO.23.00562 * Complete remission in target lesion at RP3D per image ** MRD checkpoint at 36th week of combo treatment, in patients achieved CR Cutoff date: 2026-01-26 Cutoff date: 2025-07-10 1L CLL/SLL-FDT Combo with Orelabrutinib, Ph3 registrational trial BTKi-treated MCL Registrational trial, First BCL-2 inhibitor in China to receive Breakthrough Therapy Designation r/r MZL Combo with Orelabrutinib, Ph3 registrational trial ➢ Early clinical data showed 100% ORR and 50% CRR in evaluable r/r MZL patients ➢ BTD granted by CDE for Orelabrutinib + Mesutoclax in r/r MZL after ≥1 prior therapy ➢ Ph3 IND application submitted r/r MCL Combo with Orelabrutinib, Ph3 registrational trial ➢ Mesutoclax + Orelabrutinib demonstrated encouraging activity in r/r MCL, achieving 100% ORR and 100% CRR among evaluable patients ➢ Ph3 study of Mesutoclax + Orelabrutinib in r/r MCL approved to initiate in China
Page 17
17 Venetoclax1 Lisaftoclax2 Sonrotoclax3 N=44 N=286 N=39 N=79 CRR 81.8% 66.4% 51.3% 67.1% uMRD* 86.5% 23.5% NA 52.8% SAE 20.5% 83% 43.3% 77.2% 6-month OS 90.5% 71.9% / / Mesutoclax (ICP-248): Advancing AML and MDS Programs with Significant Global Market Potential 1L AML Cutoff date: 13th Apr. 2026 Mesutoclax 1. N Engl J Med 2020;383:617-29. 2. 2024 ASCO 3. 2025. EHA 4. Nova One Advisor, Insight Code: 8817 Note: *Calculate in patients with composite complete remission 1L AML: Ph3 Mesutoclax+AZA vs. Venetoclax+AZA in China Global dose expansion MDS: Global Ph2 study ongoing Response per IWG 2006 Efficacy Evaluable N=10 ORR 100% CR 40% mCR 60% MDS Cutoff date: 20th Apr. 2026
Page 18
18 Ph3 Randomized, Open-Label, Multicenter Study of Mesutoclax + AZA vs. Venetoclax + AZA in 1L AML ▪ Patient Population: ➢ TN AML, unfit ▪ Primary Endpoints: ➢ OS ▪ Secondary Endpoints: ➢ Composite CR (cCR) ➢ MRD negativity rate EOT visit R 1:1 28 - day cycles repeated continuously until disease progression , unacceptable toxicity, or patient withdrawal Mesutoclax + AZA Mesutoclax: 125 mg QD (continuous dosing, no cycle breaks) AZA: 75 mg/m² SC Venetoclax + AZA Venetoclax: 400 mg QD (after 5-week step-up escalation) AZA: 75 mg/m² SC
Page 19
19 Mesutoclax (ICP-248): Best-in-Class Potential and Significant Market Opportunity 1L CLL/SLL Fix-duration Treatment r/r MCL AML MDS ➢ The estimated CLL/SLL patient population in China is approximately 29,000¹ . ➢ The market is currently valued in the billions of RMB and is expected to expand following the approval of fixed-duration therapies. Source:1. GBD, Frost Sullivan; 2. Song Y. et al., 2023; 3.Global Growth Insights; 4. GlobalData; 5. Nova One Advisor, Insight Code: 8817 ➢ BTK inhibitors are broadly established in treating MCL2. ➢ With growing BTKi- resistance, the unmet need for subsequent therapies is substantial. ➢ Global new AML cases are projected to increase from ~103K in 2018 to ~115K by 2028³. ➢ The global AML market was estimated at US$3.7 billion in 2024 and is expected to grow to US$8 billion by 2034³ . ➢ Global MDS patient population: approximately 500K⁴. ➢ The global myelodysplastic syndrome drugs market size was valued at US$4.6 billion in 2024 and is anticipated to reach around US$11 billion by 20345. Addressable Market Potential: ~ US$20 billion r/r MZL ➢ MZL is the second-largest NHL indication, representing a significant market opportunity. ➢ BCL-2 combination provides a significant opportunity to expand patient penetration and reinforce market leadership.
Page 20
20 Well Positioned Portfolio in Autoimmune Diseases
Page 21
21 T cell pathway B cell pathway Multiple Assets with Large Indications Progressed to Phase 3 Trials Ph3 registrational trial met its primary endpoint Global Ph3 registrational trial Orelabrutinib1 (BTKi) SLE: Systemic Lupus Erythematosus AD: Atopic Dermatitis PN: Prurigo Nodularis CLE: Cutaneous Lupus Erythematosus PPMS: Primary Progressive Multiple Sclerosis SPMS: Secondary Progressive Multiple Sclerosis ITP: Idiopathic Thrombocytopenic Purpura CSU: Chronic Spontaneous Urticaria SS: Sjögren’s Syndrome PPMS ITP SLE Ph3 registrational trial completed, NDA 2026Q2 FIC, Ph3 registrational trial, CHN AD Vitiligo PN Psoriasis Ph2/3 ongoing, Ph2 portion met its primary endpoint Global Ph2 ongoing Ph3 registrational trial met its primary endpoint 1 Zenas territories：Orelabrutinib’s MS global right and Other Autoimmune Diseases: Outside of Greater China and Southeast Asia CSU Ph2 ongoing Soficitinib (ICP-332) (TYK2i/JAK1i) Fadeucravacitinib(ICP-488) (TYK2i) Global Ph3 registrational trial SPMS CLE Ph2 ongoing Psoriasis Ph2/3 ongoing SS Ph2 ongoingEarly stage assets ICP-538(VAV1) ICP-054(IL17 small molecule) Others Ph1 ongoing Ph1 ongoing
Page 22
22 Orelabrutinib: Enormous Potential for Treating Autoimmune Diseases MS1 Source: Ehtesham N, et. al. Int Rev Immunol. 2020; 39(6):264–79. , Rarediseases.org, Frost & Sullivan, Sara Bagherieh et. Al. Neurol Sci. 2023 Jun;44(6):1905-1915. Milliman et al 2019, Lo et al. 2022, National MS Society 2025 • The world's first and only BTKi demonstrating efficacy in Ph2 trial • Phase 2b clinical trial met primary endpoints • Phase 3 clinical trial ongoing • Ph3 registrational trial for the treatment of ITP is underway in China, with NDA submitted in 2026H1 • BTKi treatment for autoimmune diseases is just around the corner • PPMS: Global Ph3 ongoing • SPMS: Global Ph3 ongoing • Best-in-class potential • Current SPMS and PPMS commercial opportunity in the U.S. alone projected to be >$12B+2, expected to grow significantly with approval of effective therapies that impact disease progression SPMS & PPMS could represent >40% of all MS diagnoses Over 200,000 new patients globally each year ~8 million patients worldwide Orelabrutinib ITP1 SLE1 1 Zenas territories：Orelabrutinib’s MS global right and Other Autoimmune Diseases: Outside of Greater China and Southeast Asia; 2. Zenas estimate based on reported prevalence and current pricing of B cell therapies approved for MS
Page 23
23 Orelabrutinib in ITP: Large Market Opportunity Approaching NDA Current Therapy Limitations Steroids & IVIG Short-term benefit, significant side effects TPO-RA Risk of thrombotic events, decreased efficacy with prolonged treatment Others Lack of durable, safe oral options Disease & Patient Population • ITP (Immune Thrombocytopenia) is a chronic autoimmune bleeding disorder with significant relapse rates after first-line therapy. • ~300,000 chronic patients in China • ~60,000 new cases annually Current Treatment Gaps Orelabrutinib’s Advantage Market Potential Key Milestones Inhibits abnormal B-cell activation & autoantibody production with wider safety margin and convenient oral dosing China’s large ITP patient base and growing diagnosis rate create a significant market opportunity worth hundreds of millions USD 2026 H1: NDA submitted and accepted by CDE Poised to address the significant unmet needs in ITP – strong potential to become the next growth driver.
Page 24
24 Orelabrutinib in SLE: Global First-in-Class BTK Inhibitor with Large Market Opportunity Current Therapy Limitations Corticosteroids & Immunosuppressants Significant toxicity, poor long-term safety, frequent relapse after dose reduction Biologics High cost, IV or SC administration, partial response in many patients Others Lack of durable, safe oral options First-in-Class potential, unlocking a multi-billion-dollar market opportunity. ➢ Ph3 registrational trial ongoing Orelabrutinib’s Advantage • Selective BTK inhibition to suppress B-cell activation and autoantibody production • Oral dosing with favorable safety and tolerability • Potential to become the first-in-class oral BTK inhibitor for SLE, offering improved convenience and disease control • Large and underserved SLE population with increasing diagnosis rates • Biologics market for SLE already exceeds US$3 billion globally, expected to grow rapidly with more accessible oral options • SLE is a chronic autoimmune disease affecting multiple organs. • ~8 million patients globally; ~1 million in China1. • Most common in young and middle-aged women; chronic management needed for years or decades. SLE Current Treatment Gaps Market Potential 1. doi: 10.2478/rir-2022-0006
Page 25
25 Active site binding ICP-332, ICP-488: TYK2 Inhibitors with Different Selectivity Profiles Note: The picture adopted from Cell 2022, 185, 3857-3876. & Lombardo, SAPA Symposium 2020. JH2 (pseudokinase domain) JH1 (kinase domain) Blocking the ATP binding site Inactive state Allosteric site binding Inhibitor IC50 (nM) IC50 (nM) @1 mM ATP TYK2 JH2 TYK2 JH1 JAK1 JAK2 JAK3 ICP-332 2319 0.5 19 191 930 ICP-488 5 >10,000
Page 26
26 Soficitinib (ICP-332): Shows Outstanding EASI 75 Improvement and Rapid Itch Reduction in Ph2 Atopic Dermatitis (AD) Trial 56.0% 53.3% 46.8% 27.9% 34.1% 9.9% 11.8% 36.0% 32.0% 12.1% 21.6% 42.0% 33.3% ICP-332(TYK2/JAK1) ph2 80mg qd 4w Upadacitinib(JAK1) ph3(Measure Up 1) 15mg qd 16w1 Upadacitinib(JAK1) ph3(Measure Up 2) 15mg qd 16w2 Abrocitinib (JAK1) ph3(JADE MONO-1) 100mg qd 12w3 Abrocitinib(JAK1) ph3(JADE MONO-2) 100mg qd 12w4 Baricitinib(JAK1/2) ph3(BREEZE-AD1) 2mg qd 16w5 Baricitinib(JAK1/2) ph3(BREEZE-AD2) 2mg qd 16w6 Dupliumab(IL-4Rα) ph3(SOLO-1) 16w7 Dupliumab(IL-4Rα) ph3(SOLO-2) 16w7 Tralokinumab(IL-13) ph3(ECZTRA-1) 16w8 Tralokinumab(IL-13) ph3(ECZTRA-2) 16w8 Lebrikizumab(IL-13) ph3(ADvocate1) 16w9 Lebrikizumab(IL-13) ph3(ADvocate2) 16w9 # Not a head-to-head comparison Phase 2 data indicates that soficitinib demonstrates significant efficacy in treating AD, showing the best efficacy on EASI 75 (placebo-adjusted) compared to several other innovative drugs Soficitinib (ICP-332) Ph2 AD Visit Pruritus Numerical Rating Scale Source：1,2,3,4,5,6: data from ClinicalTrials.gov https://www.clinicaltrials.gov/ 7. DUPIXENT® (dupilumab) injection label. 8. A. Wollenberg, et al. Br J Dermatol 2021; 184:386 –387 DOI 10.1111/bjd.19574. 9. Silverberg JI,et al. N Engl J Med . 2023 Mar 23;388(12):1080-1091. doi:
Page 27
27 Soficitinib (ICP-332): Showed Excellent Efficacy in Ph3 AD Study with All Primary Endpoint Met A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis (NCT06775860) ▪ Patient Population: ➢ EASI ≥ 16 ➢ ≥ 10% BSA ➢ vIGA-AD ≥ 3 ➢ Baseline average WP-NRS ≥ 4 ▪ CO-Primary Endpoints: ➢ EASI 75 at W16 ➢ vlGA 0/1 and ≥ 2 points reduction at W16 ▪ Secondary Endpoints: ➢ EASI 50 /75 /90 /100 ➢ vIGA 0/1 and ≥ 2 points reduction ➢ NRS 0/1 ➢ Improvement of Worst Pruritus NRS ≥ 4 ➢ Time to achieve improvement of Worst Pruritus NRS ≥ 4 Safety follow-up (4 weeks) Double blinded (16 weeks) Maintenance treatment (36 weeks) N=552 W16 Primary Endpoint Soficitinib 80 mg QD (n=368) Placebo (n=184) Soficitinib 80 mg QD R 2:1 W52 EOT ➢ 16-week efficacy primary endpoints successfully met, marking a key clinical milestone ➢ 52-week safety follow-up ongoing, with NDA submission planned upon completion
Page 28
28 Soficitinib (ICP-332): Positive Ph2 Vitiligo Results Pave the Way for Ph3 A phase 2/3 randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo (NCT07047612) ▪ Patient Population: ➢ Non-segmental vitiligo subjects ▪ Primary Endpoints: ➢ F-VASI change from baseline at W24 ▪ Secondary Endpoints: ➢ F-VASI 50/75/90/100 ➢ T-VASI 50/75/90/100 ➢ PGIS-F ➢ PGIS-V ➢ VNS 4 / 5 ➢ HADS ➢ VitiQoL ➢ Safety ➢ PK and biomarker Safety follow-up (4 weeks) Double blinded (24 weeks) Double blinded extension (28 weeks) N=159 W24 Primary Endpoint Soficitinib 120 mg QD (n=53) Placebo (n=53) Soficitinib 80 mg QD W52 EOT Soficitinib 80 mg QD (n=53) R 1:1:1 Soficitinib 120 mg QD ➢ Ph2 vitiligo study met its primary endpoint, demonstrating positive clinical efficacy ➢ Ph3 initiation underway, advancing the program toward pivotal development
Page 29
29 Soficitinib (ICP-332) Ph2 Vitiligo Study: Primary End Point Met with Excellent Efficacy on F-VASI Improvement from Baseline at W24 F-VASI Improvement from Baseline at W24 14.4% 5.1% -2.1% 2.2% 22.0% 27.7% 3.0% 35.6% 36.4% 14.6% 34.0% 29.4% 18.5% 21.2% 21.2% -5% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 38.8%**** 41.2%**** Soficitinib Ph 2 Vitiligo Study Upadacitinib Ph 2 Vitiligo Study1 Povorcitinib Ph 2 Vitiligo Study2 Ritlecitinib Ph 2 Vitiligo Study3 Source: 1. eClinicalMedicine 2024;73: 102655 2. Journal of the American Academy of Dermatology, 2025; 93, 946-955 3. Fortebiorx Corporate deck https://www.fortebiorx.com/ ****: P<0.0001
Page 30
30 Soficitinib (ICP-332): Enormous Potential for Treating Inflammatory Skin Diseases 1. Grand View Research; 2. https://doi.org/10.1093/bjd/ljad339; 3. Data Bridge Market Research; 4. Global Vitiligo Foundation ; 5. The Business Research Company; 6. DOI: 10.1007/s12325-025-03172-0; 7. Fortune Business Insights; 8. International Federation of Psoriasis Associations (IFPA); 9. Global Market Insights; 10. https://doi.org/10.1111/jdv.20585 ICP-332 Atopic Dermatitis (AD) • Ph3 met primary endpoints; NDA submission planned in 2027H1. • TYK2/JAK1 inhibitor blocks key cytokine signaling pathways: IL-4, IL-13, IL- 31, and TSLP, suppressing Th2-driven inflammation and alleviating atopic dermatitis symptoms. • Global drug-market for AD: estimated at US$18 billion in 2024, projected to reach ~ US$30 billion by 20301. ~200 million patients worldwide2 • Ph2 positive; Ph3 initiation underway. • TYK2/JAK1 inhibitor blocks IFN-γ and IL-15– mediated JAK-STAT signaling, suppressing T- cell attacks on melanocytes and promoting repigmentation. • The global vitiligo treatment market size was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 20323. ~70 million patients worldwide4 ICP-332 Vitiligo • Ph2/3 ongoing; Ph2 enrollment completed, with data readout expected by YE2026. • TYK2/JAK1 inhibitor blocks cytokine signaling pathways: IL-4, IL-13, and IL-31 that drive mast cell activation and inflammation, reducing itch and wheal formation in CSU. • The global CSU treatment market has reached to US$2 billion in 2024 and expected to grow to US$3 billion in 20295. ICP-332 CSU ~50 million patients worldwide6 • Ph2 enrollment completed; data readout expected by YE2026. • Dual TYK2/JAK1 pathway modulation suppresses IL- 23/Th17 signaling and multiple pro-inflammatory cytokines, reducing inflammation and normalizing keratinocyte hyperproliferation. • Global psoriasis treatment market: ~US$27 billion in 2024, projected to reach ~US$58 billion by 203217. ICP-332 Psoriasis 240 million patients worldwide8 Data coming in the next few months. • Global Ph2 ongoing. • TYK2/JAK1 inhibitor blocks cytokine signaling pathways: IL-4, IL-13, and IL-31, reducing neurogenic pruritus and alleviating PN symptoms. • The global PN market was valued at US$2 billion in 2024 and is expected to grow to US$3 billion in 20349. ~10 million patients globally10 ICP-332 Prurigo Nodularis (PN) Met primary endpoint(s).
Page 31
31 Fadeucravacitinib (ICP-488): Shows Strong Efficacy in Ph2 Plaque Psoriasis All randomized subjects were included in the FAS analysis. p values from a Cochran-Mantel-Haenszel test, with prior biologic treatment included as a stratification factor, comparing the proportion of patients in the treatment group versus placebo. PASI, Psoriasis Area and Severity Index; QD, once daily; NRI, non-responder imputation 11.6% 77.3% 78.6% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% PASI 75 Patients achieving PASI 75 at Week 12 (FAS) Placebo(N=43) ICP-488 6mg QD(N=44) ICP-488 9mg QD (N=42) 0.0% 2.3% 4.7% 11.6%13.6%* 38.6%* 77.3%* 14.3%* 59.5%* 78.6%* 0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 80.00% 90.00% W0 W4 W8 W12 PASI 75 Response Rate by visit (FAS) Placebo(N=43) ICP-488 6mg QD(N=44) ICP-488 9mg (N=42) *** p<0.0001 *** *** *Unilateral p<0.05 Response Rate Response Rate Time (week)
Page 32
32 A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ICP-488 in subjects with moderate to severe plaque psoriasis (NCT06842199) ▪ Patient Population: ➢ PASI≥12 ➢ BSA≥10% ➢ sPGA≥3 ▪ CO-Primary Endpoints: ➢ PASI 75 at W16 ➢ sPGA 0/1 and ≥ 2 points reduction at W16 ▪ Secondary Endpoints: ➢ PASI 50 /75 /90 /100 ➢ sPGA 0/1 Safety follow-up (4 weeks) Double blinded (16 weeks) Maintenance treatment (36 weeks) N=360 W16 Primary Endpoint Fadeucravacitinib 9 mg QD (n=240) Placebo (n=120) Fadeucravacitinib 9 mg QD R 2:1 W52 EOT Fadeucravacitinib (ICP-488): Showed Excellent Efficacy in Ph3 Psoriasis Study with All Primary Endpoint Met ➢ 16-week efficacy primary endpoints successfully met, marking a key clinical milestone ➢ 52-week safety follow-up ongoing
Page 33
33 Fadeucravacitinib (ICP-488): Leveraging Strong Efficacy and Safety Profile, Unlocking Broader Market Potential • Ph3 met primary endpoints. • TYK2 allosteric inhibitor with potential to achieve best-in- class efficacy and safety. • Global psoriasis treatment market: ~US$27 billion in 2024, projected to reach ~US$58 billion by 203211. ICP-488 Psoriasis 240 million patients worldwide2 • Ph2 ongoing. • TYK2 allosteric inhibitor with potential to address high unmet need in CLE, targeting the Type I interferon pathway central to lupus pathogenesis. • Global market estimated at ~US$2.9B in 2024, projected to reach ~US$7.9B by 20323. ICP-488 CLE ~800,000 diagnosed patients across major markets4 • SLE: ~8 million patients globally; ~1 million in China7 • IBD: ~US$23.6B in 2024, projected to reach ~US$35.7B by 20328 • Psoriatic arthritis: ~US$11B market growing to >US$20B by 20309 ICP-488 Broad immunology platform Target indications represent a combined global market opportunity of >US$150B10 1. Fortune Business Insights; 2. International Federation of Psoriasis Associations (IFPA); 3,8. Data Bridge Market Research; 4. https://www.openpr.com/news/4176533/cutaneous-lupus-erythematosus-market-epidemiology 5. wiseguyreports; 6. delveinsight; 7. doi: 10.2478/rir-2022-0006; 9. Grand View Research; 10. Alumis ICP-488 Sjögren’s syndrome 3.3 million diagnosed cases across major markets6 • Ph2 ongoing. • TYK2 allosteric inhibitor modulate type I interferon and interleukin signaling pathways, underlying immune dysregulation of Sjögren’s syndrome. • Global Sjögren’s syndrome market was ~USD 3.02 billion in 2024, projected to reach ~USD 5.5 billion by 20355. Met primary endpoint(s).
Page 34
34 VAV1Program Development Strategy Ref: Monte Rosa Q4 and full year 2024 earnings call and pipeline update. ❑ VAV1 is a promising target involved in both T-cell and B-cell pathways that could be used for the treatment of various autoimmune diseases ❑ It’s proposed that VAV1 targeted therapy could provide much better efficacy in some of the hard-to-treat autoimmune diseases ❑ ICP-538: a potent and selective VAV1 degrader. Phase I ongoing with SAD/MAD escalation cohorts underway Potential in treating various autoimmune diseases including hard-to-treat indications
Page 35
35 ICP-538: A Potent CRBN-Mediated VAV1 Molecular Glue Degrader with Strong Anti-Inflammatory Efficacy -2 0 2 4 -20 0 20 40 60 80 100 120 Dose-response VAV1 degradation (Jurkat cells) Compound conc. [Log (nM)] Vav1 (% of control) MRT-Ref ICP-538 Rapid and deep VAV1 degradation 0 1 2 4 6 24 48 -20 0 20 40 60 80 100 120 VAV1 degradation kinetics of ICP- 538 (Jurkat cells) Treatment hours VAV1 (% of Control) ICP-538, 1 μM MRT-Ref, 1 μM Vehicle Note: VAV1 degradation was tested in Jurkat cells. VAV1 degradation dynamics in Jurkat cells 0 2 4 6 8 10 12 14 16 2 4 6 8 10 12 Days after treatment Clinical Score Normal Vehicle, PO, QD ICP-538, 0.3 mg/kg, PO, QD ICP-538, 1 mg/kg, PO, QD ICP-538, 3 mg/kg, PO, QD ****** **** * CIA: collagen-induced arthritis ICP-538 Inhibits Rat CIA Progression VAV1 degradation dynamics in Jurkat cells Dose-response VAV1 degradation Competitor Competitor
Page 36
36 Reference: https://media.nature.com/full/naturecms/uploads/ckeditor/attachments/8204/interleukin17.pdf Mechanism of Action of IL-17 Inhibitor Target Indications IL-17: A Valid Autoimmune Disease Target
Page 37
37 ICP-054: A Novel Small-Molecule IL-17 Inhibitor for Autoimmune Diseases with Potent Activity Against Both IL-17AA and IL-17AF IL-17 modulator (PPI) In vivo efficacy in rat CIA model CMPD Binding IC50 (nM) IL-17 Signaling IC50 (nM)@HEK-Blue IL-17 Signaling IC50 (nM)@HEK–Blue Th17 SupernatantIL-17AA IL-17AF ICP-054 2.6 ± 1.7 6.5 ± 3.1 18.4 ± 16.2 2.8 ± 3.4 ICP-054 • Potent against IL-17AA & AF • Excellent PK • Phase I ongoing with SAD/MAD escalation cohorts underway. ICP-054 is potent against both IL-17AA and AF 0 2 4 6 8 10 12 14 2 3 4 5 6 7 8 9 Days after treatment Clinical Score Normal control Vehicle, PO, QD Anti-IL-17 biologic ICP-054, 0.3 mg/kg ICP-054, 1 mg/kg ICP-054, 3 mg/kg ICP-054, 10 mg/kg *ICP-054 partnered with Zenas BioPharma (Nasdaq: ZBIO)
Page 38
38 Innovative Therapies for Comprehensive Coverage of Autoimmune Diseases Orelabrutinib (BTKi) Soficitinib (ICP-332) (TYK2/JAK1i) Fadeucravacitinib (ICP-488) (TYK2i) ICP-538 (VAV1 molecular glue) ICP-054 (IL-17 small molecule) AA: Aplastic anemia AIHA: Autoimmune hemolytic anemia NMO: Neuromyelitis optica MG:Myasthenia gravis CLE: Cutaneous Lupus Erythematosus MoG-EN: MOG antibody-associated encephalomyelitis SS: Sjö gren syndrome RA: Rheumatoid Arthritis IgG4 RD:IgG4 related disease LN: Lupus Nephritis MN: membranous nephropathy UC:Ulcerative Colitis CD: Crohn disease CSU: Chronic Spontaneous Urticaria ITP PPMS SLE SPMS RA AD PSO SS AIHA MG UC CD AA LN MN InnoCare current coverage Vitiligo Prurigo Nodularis NMO MoG-EM Project 42 (molecular glue degrader) Project 40 (bi-specific antibody) Project 43 (PROTAC) Project 44 (small molecule) Clinical Pre-clinical Neurology Rheumatology Hematology Dermatology Gastroenterology Nephrology PSACLE CSU CLE
Page 39
39 Innovative Solid Tumor Assets
Page 40
40 Zurletrectinib (ICP-723): 2nd Generation TRKi for NTRK Tumors • 2nd Generation TRKi for Tumors with NTRK Gene Abnormalities – NDA for adults and adolescents patients, approved in Dec. 2025 • Registration trial for NTRK gene abnormalities in adults and adolescents ✓ ORR: 89.1% (95% CI: 77.8, 95.9） ✓ Long duration of response (longest beyond 36 months) ✓ Efficacious in TRKi-resistant patients • NDA submission for pediatric patients submitted in 2Q2026 ✓ IRC-assessed ORR: 100% (95% CI: 69.2, 100.0), with 10% CR and 90% PR as of July 11, 2026 Data cut-off：2024-11-23 Significant and durable efficacy observed across diverse tumor types in adult patients
Page 41
41 Design & Advantage of InnoCare’s Proprietary ADC Platform Effective PayloadHydrophilic LinkerNovel Connector • Irreversible connector • Prevents thiol exchange • Potent • Bystander effect • Tumor-specific release • Rapid clearance • Allows high DAR • Improves stability Linker Cleavable Novel antibody
Page 42
42 CDH17: A Potent Target for the Treatment of GI Cancers Cancer cell Lysosome Nucleus TOPO1Payload CDH17 ICP-B208 CDH17positive cells CDH17negative cells Cell apoptosis Normal cells: CDH17 is hidden in tight junctions - - - - Cancer cells: redistribution of CDH17, and making it accessible
Page 43
43 ICP-B208 (CDH17 ADC): Demonstrates Robust Anti-tumor Activity Even in CDH17-low Tumors Gp2d (CDH17-low colorectal cancer) 0 5 10 15 20 25 30 35 0 200 400 600 800 1000 1200 Days after Treatment Tumor volume (mm3) Gp2d CDX model Vehicle, IV HS-20110, 3 mg/kg, IV ICP-B208, 0.3 mg/kg, IV ICP-B208, 1 mg/kg, IV ICP-B208, 3 mg/kg, IV TGI:80.39%**** TGI:100.81%**** TGI:116.38%**** TGI:44.10%*SUN-16 (CDH17-high gastric cancer) 0 10 20 30 40 50 60 70 80 0 400 800 1200 1600 Days after treatment Tumor volume (mm3) SNU-16 CDX model HS-20110, 3 mg/kg Vehicle ICP-B208, 0.3 mg/kg ICP-B208, 1 mg/kg ICP-B208, 3 mg/kg i.v. i.v. ** **** **** **** Note： P value was calculated based on tumor volume on day 40 vs vehicle group, **P < 0.01, ****P < 0.0001; HS-20110, a CDH17-ADC developed by Hansoh Pharmaceutical. ✓ ICP-B208 is a highly potent CDH17 ADC with robust anti-tumor activity even in CDH17-low tumors • ICP-B208 Phase I trial on-going for the treatment of gastrointestinal tumors XXX, XXX, XXX: Clinically leading CDH17-targeting ADC
Page 44
44 STEAP1/PSMA ADC: Dual-Targeting Design Expands Tumor Coverage and Addresses Antigen Heterogeneity Heterogeneity in PSMA and STEAP1 expression ✓ Potential for enhanced activity when both antigens are presented ✓ Good efficacy even at low target expression levels ✓ Overcoming drug resistance mediated by loss of either antigen ✓ IND submitted and accepted by CDE ✓ U.S. IND filing expected in Sept. 2026 STEAP1PSMA Dual target binding STEAP1 binding PSMA binding Dual Target Binding of PSMA/STEAP1 ADC Heterogeneity in absolute levels STEAP1 Single or double populations PSMA Inter-tumor Heterogeneity Intra-tumor Heterogeneity Antigen loss driven by therapeutic pressure, lineage plasticity, etc. Heterogeneity in PSMA and STEAP1 Expression Tumor Relapse Caused by Antigen Loss
Page 45
45 ICP-B381: Demonstrates Robust and Dose-Dependent In Vivo Antitumor Activity Robust in vivo antitumor activity 0 5 10 15 20 0 500 1000 1500 2000 Days after treatment Tumor volume (mm3) 22RV1 (PSMAlow/STEAP1ultra-low) Vehicle STEAP1 ADC, 1 mg/kg PSMA ADC, 1 mg/kg ICP-B381 BsADC, 1 mg/kg i.v. TGI：73.28% **** TGI：81.11% **** TGI：93.81% **** XXX BsADC, 1 mg/kg TGI: 55.59%**** Dose-dependent antitumor activity 0 5 10 15 20 25 0 500 1000 1500 2000 Days after treatment Tumor volume (mm3) 22RV1 (PSMAlow/STEAP1ultra-low) Vehicle ICP-B381 BsADC, 0.1 mg/kg ICP-B381 BsADC, 0.3 mg/kg ICP-B381 BsADC, 1 mg/kg i.v. TGI: 20.09% TGI: 44.68%**** TGI: 90.46%**** XXX BsADC, 1 mg/kg TGI: 31.12%**
Page 46
46 ADC Platform Advantages and Pipeline Progress • ICP-B794 (B7H3 Target ADC) ✓ Ph1 ongoing in advanced solid tumors ✓ Dose level 5 completed and dose level 6 initiated • ICP-B208 (CDH17 Target ADC) ✓ Ph1 trial on-going for the treatment of gastrointestinal tumors • ICP-B381 (STEAP1/PSMA BsAb ADC) ✓ IND submitted and accepted by CDE for the treatment of prostate cancer ✓ U.S. IND filing expected in Sept. 2026 • Irreversible linker enabling high DAR (~8) • Rapid payload clearance supporting a wide therapeutic window (>250×) • Potent payload with activity against large tumors and upon rechallenge
Page 47
47 Key Upcoming Events Assets Milestones Hemato-oncology Orelabrutinib & Mesutoclax (ICP-248) - Ph3 registrational trial of Orelabrutinib + Mesutoclax in 1L CLL/SLL-FDT data readout & NDA submission - Completion of the registration trial for BTKi-treated MCL & NDA submission - Ph3 initiation for r/r MCL & r/r MZL, Mesutoclax + Orelabrutinib - Ph3 initiation for 1L AML, Mesutoclax + AZA vs venetoclax + AZA - MDS: Global Phase II completion, advancing toward Phase III Autoimmune Diseases Orelabrutinib - ITP NDA Approval - Accelerate patient enrollment of SLE Ph3 registration trial - Zenas-partnered PPMS/SPMS global Ph3 programs: rapid advancement and accelerated execution Soficitinib (ICP-332) - Ph3 AD, safety follow-up completion and NDA submission - Ph2/3 vitiligo, Ph3 initiation - Ph2/3 CSU & Ph2 psoriasis, Ph2 portion data readout, Ph3 initiation - Finish Global Ph2 trial in PN Fadeucravacitinib (ICP-488) - Ph3 psoriasis, safety follow-up completion - Ph2 trial in CLE & SS, accelerate patient enrollment - Explore new indications ICP-538 (VAV1) - Completion of Ph1 & data readout ICP-054 (IL-17i) - Completion of Ph1 & data readout Solid Tumor ICP-B794 (B7H3 ADC) - Dose expansion completed; recommended dose established ICP-B208 (CDH17 ADC) - Dose escalation data readout and dose expansion ICP-B381(STEAP1/PSMA ADC) - IND approval and FPI in China & US Sustained Profitability Sustain profit-positive performance throughout 2026
Page 48
48 Thank you for your attention！